Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
Amgen Inc
Cadila Healthcare Ltd
Caldan Therapeutics Ltd
Hyundai Pharma Co Ltd
Il Dong Pharmaceutical Co Ltd
Johnson & Johnson
Limil BioSciences Inc
Merck & Co Inc
Scohia Pharma Inc
Takeda Pharmaceutical Co Ltd
TiumBio Co Ltd
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
AM-3189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasiglifam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDG-16177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-267 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYDG-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
Featured News & Press Releases
Sep 15, 2020: Conference presentation on medicil chemistry research of GPR40 full agonist (SCO-267)
Sep 10, 2020: GPR40 full agonist (SCO-267) medicil chemistry research
Nov 18, 2019: Limil presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmory Arterial Hypertension
Nov 12, 2019: Limil BioSciences presents new preclinical data on PBI-4050
Nov 11, 2019: Limil Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
Oct 25, 2019: Limil BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
Oct 24, 2019: Limil BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association’s 79th Scientific Sessions
May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
Aug 10, 2018: Prometic announces the publication of PBI-4050’s antifibrotic activity in liver diseases in jourl of pharmacology and experimental therapeutics
Aug 07, 2018: Prometic receives rare pediatric disease desigtion from U.S. FDA for small molecule drug candidate PBI-4050
May 22, 2018: Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmory fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Cadila Healthcare Ltd, H2 2020
Pipeline by Caldan Therapeutics Ltd, H2 2020
Pipeline by Hyundai Pharma Co Ltd, H2 2020
Pipeline by Il Dong Pharmaceutical Co Ltd, H2 2020
Pipeline by Johnson & Johnson, H2 2020
Pipeline by Liminal BioSciences Inc, H2 2020
Pipeline by Merck & Co Inc, H2 2020
Pipeline by Scohia Pharma Inc, H2 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
Pipeline by TiumBio Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020